技术与方法 |
|
|
|
|
PD-L1基因敲除小鼠构建及初步表型验证 |
万颖寒1,慈磊3,*,王珏1,龚慧1,李俊1,董茹1,孙瑞林3,费俭2,3,沈如凌1,**() |
1 模式生物及比较医学研究联合实验室 上海实验动物研究中心 上海 201203 2 同济大学生命科学与技术学院 上海 200092 3 上海南方模式生物科技股份有限公司 上海 201318 |
|
Construction and Preliminary Phenotypic Verification of PD-L1 Knockout Mice |
WAN Ying-han1,CI Lei3,*,WANG Jue1,GONG Hui1,LI Jun1,DONG Ru1,SUN Rui-lin3,FEI Jian2,3,SHEN Ru-ling1,**() |
1 Joint Laboratory of Model Biology and Comparative Medical Research,Shanghai Laboratory Animal Research Center,Shanghai 201210,China 2 School of Life Science and Technology, Tongji University, Shanghai 200092, China 3 Shanghai Model Organisms Center,Shanghai 201318,China |
引用本文:
万颖寒,慈磊,王珏,龚慧,李俊,董茹,孙瑞林,费俭,沈如凌. PD-L1基因敲除小鼠构建及初步表型验证[J]. 中国生物工程杂志, 2019, 39(12): 42-49.
WAN Ying-han,CI Lei,WANG Jue,GONG Hui,LI Jun,DONG Ru,SUN Rui-lin,FEI Jian,SHEN Ru-ling. Construction and Preliminary Phenotypic Verification of PD-L1 Knockout Mice. China Biotechnology, 2019, 39(12): 42-49.
链接本文:
https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.20191206
或
https://manu60.magtech.com.cn/biotech/CN/Y2019/V39/I12/42
|
[1] |
Shi Y Y . Regulatory mechanisms of PD-L1 expression in cancer cells. Cancer Immunol Immun, 2018,67(10):1481-1489.
|
[2] |
Keir M E, Butte M J, Freeman G J , et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol, 2008,26:677-704.
|
[3] |
Dong H D, Strome S E, Matteson E L , et al. Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J Clin Invest, 2003,111(3):363-370.
|
[4] |
Yamazaki T, Akiba H, Iwai H , et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol, 2002,169(10):5538-5545.
|
[5] |
Dong H D, Chen X M . Immunoregulatory role of B7-H1 in chronicity of inflammatory responses. Cell Mol Immunol, 2006,3(3):179-187.
|
[6] |
Okazaki T, Honjo T . PD-1 and PD-1 ligands: from discovery to clinical application. International Immunology, 2007,19(7):813-824.
|
[7] |
Dong H D, Zhu G F, Tamada K , et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med, 1999,5(12):1365-1369.
|
[8] |
Dong H D, Strome S E, Salomao D R , et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med, 2002,8(8):793-800.
|
[9] |
Terawaki S, Chikuma S, Shibayama S , et al. IFN-alpha directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol, 2011,186(5):2772-2779.
|
[10] |
Brown J A, Dorfman D M, Ma F R , et al. Blockade of programmed death-1 Ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol, 2003,170(3):1257-1266.
|
[11] |
Azuma T, Yao S, Zhu G , et al. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood, 2008,111(7):3635-3643.
|
[12] |
Hofmeyer K A, Jeon H, Zang X X. The PD-1/PD-L1 (B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion.[2011-9-25].
|
[13] |
Tsushima F, Yao S, Shin T , et al. Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood, 2007,110(1):180-185.
|
[14] |
Yang B, Liu T J, Qu Y , et al. Progresses and perspectives of anti-PD-1/PD-L1 antibody therapy in head and neck cancers. Front Oncol, 2018,8:563.
|
[15] |
Armand P . Immune checkpoint blockade in hematologic malignancies. Blood, 2015,125(22):3393-3400.
|
[16] |
Katz H, Wassie E, Alsharedi M . Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer. Med Oncol, 2017,34(10):170.
|
[17] |
Buttner R, Gosney J R, Skov B G , et al. Programmed death-ligand 1 immunohistochemistry testing: A review of analytical assays and clinical implementation in non-small-cell lung cancer. J Clin Oncol, 2017,35(34):3867.
|
[18] |
Weber J S ,D’Angelo S P,Minor D, et al.Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol, 2015,16(4):375-384.
|
[19] |
Wainberg Z A, Hochster H S, George B , et al. Phase I study of nivolumab (nivo) plus nab-paclitaxel (nab-P) +/- gemcitabine (Gem) in solid tumors: Interim results from the pancreatic cancer (PC) cohorts. J Clin Oncol, 2017,35(4):412.
|
[20] |
El-Khoueiry A B, Melero I, Yau T C , et al. Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040. J Clin Oncol, 2018,36(4):475-475.
|
[21] |
Fuchs C S ,Doi T,Jang R W J, et al.KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patientsx with previously treated advanced gastric cancer. JAMA Oncol.[2018-3-15].
|
[22] |
Homet Moreno B, Ribas A . Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. British Journal of Cancer, 2015,112(9):1421-1427.
|
[23] |
Topalian S L, Drake C G, Pardoll D M . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell, 2015,27(4):450-461.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|